Trial Profile
A study evaluating effect of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Feb 2018
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Etanercept (Primary) ; Infliximab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms PREDIR
- Sponsors Pfizer
- 27 Feb 2018 New trial record